Steve Seedhouse

Stock Analyst at Cantor Fitzgerald

(3.38)
# 962
Out of 5,131 analysts
14
Total ratings
69.23%
Success rate
2.34%
Average return

Stocks Rated by Steve Seedhouse

Wave Life Sciences
Feb 5, 2026
Maintains: Overweight
Price Target: $34$41
Current: $12.68
Upside: +223.34%
Korro Bio
Jan 28, 2026
Upgrades: Overweight
Price Target: $21
Current: $11.17
Upside: +88.00%
Apellis Pharmaceuticals
Jan 13, 2026
Maintains: Overweight
Price Target: $39$35
Current: $21.70
Upside: +61.29%
Belite Bio
Nov 24, 2025
Assumes: Overweight
Price Target: $154
Current: $175.70
Upside: -12.35%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $40$42
Current: $11.60
Upside: +262.07%
Innoviva
Nov 6, 2025
Maintains: Overweight
Price Target: $29$31
Current: $22.72
Upside: +36.44%
Camp4 Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: $7
Current: $3.85
Upside: +81.82%
Tvardi Therapeutics
Jul 11, 2025
Initiates: Overweight
Price Target: $52
Current: $3.72
Upside: +1,297.85%
Harrow
Jul 11, 2025
Initiates: Overweight
Price Target: $76
Current: $47.69
Upside: +59.36%